RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
BGI Genomics of Shenzhen formed a $50 million partnership with US-based Natera to commercialize Natera’s Signatera™ MRD (minimal residual disease) test in China. Natera says Signatera is the first circulating tumor DNA test designed to monitor molecular treatment and assess MRD. The two companies will also work together to develop reproductive health tests in select markets on BGI’s sequencing instruments using its DNBseq™ NGS technology platform. Under the 10-year agreement, BGI will pay Natera $50 million, made up of upfront licensing fees, prepaid royalties, and future milestones.
Source: China Biotoday